En Es
Categories

Industry News

AI-Based Mammography Software Receives FDA Clearance

By Medimaging International staff writers
05 Apr 2019

Image: The cmTriage software enables a radiologist to customize, sort, and prioritize their mammography worklist based on cases that may need immediate attention (Photo courtesy of CureMetrix).CureMetrix (La Jolla, CA, USA) has received clearance from the US Food and Drug Administration to market cmTriage, a workflow optimization tool that enables a radiologist to customize, sort, and prioritize their mammography worklist based on cases that may need immediate attention.

CureMetrix is a healthcare technology company that develops computer-aided detection (CAD) software based on artificial intelligence (AI) for medical image analysis. Instead of today’s method of first in, first out for reading through a screening mammography worklist, radiologists can now use CureMetrix cmTriage to identify which cases are suspicious and focus on those first. They can also use cmTriage to optimize their clinical workflow by sending the suspicious cases to their most senior radiologists or reading the suspicious cases immediately before the patient has even left the clinic. CureMetrix cmTriage has an area under the curve (AUC) of 0.95. With this high level of efficacy, radiologists can expect cmTriage to highlight the suspicious cases without excessive false positives.

“Early and accurate detection in breast cancer is key in improving cancer survival rates worldwide through the development of next generation medical image analysis solutions. With 40 million mammograms a year in the US, only five cancers per 1,000 are being found at screening. cmTriage allows the radiologist to prioritize their worklist, creating the potential to help doctors move more quickly through their reviews and find those cancers by highlighting the suspicious cases. “Our ability to bring cmTriage to the medical community is a major milestone in our mission to deliver CAD that Works to support the radiologist and the patients they serve,” said Kevin Harris, CEO and Board Director for CureMetrix.

“Our goal is to provide radiologists with analytic tools to enhance diagnosis in breast cancer screening and augment treatment decisions,” said Lisa Watanabe, M.D., Chief Medical Officer at CureMetrix and Clinical Associate Professor at University of Southern California. “On average, early signs of breast cancer may be missed up to 50% of the time on mammograms. Analysis of mammograms with cmTriage has the potential to help radiologists focus on the suspicious cases and increase their productivity. This will allow for more time to engage with our patients and the healthcare team. Providing radiologists with the most advanced technology and tools like cmTriage to support their evaluation of mammograms will lead to improved clinical outcomes, reduced healthcare costs and increased assurance that patients are receiving high quality and accurate clinical care.”

Related Links:
CureMetrix



E-mail Print
FaceBook Twitter Google+ Linked in

Additional news

24 Apr 2019
New AI System Performs As Well As Radiologists in Detecting Prostate Cancer
Researchers from the University of California have developed a new artificial intelligence (AI) system to help radiologists improve their ability to diagnose prostate cancer.
Read More
24 Apr 2019
New Roadmap Outlines AI Research Priorities for Medical Imaging
A report establishing a research roadmap outlining priorities in foundational and translational research in artificial intelligence (AI) for medical imaging has been published in the journal Radiology.
Read More
18 Apr 2019
AI Algorithm Detects Breast Cancer in MR Images
A team of researchers from Memorial Sloan Kettering Cancer Center have trained a smart algorithm on a neural network to recognize the appearance of breast cancer in MR images.
Read More
18 Apr 2019
Wireless Syringe Pumps a Key Trend in Global Syringe Pump Market
The global smart syringe pumps market is projected to grow at a CAGR of close to 9% during the forecast period 2019-2023, driven primarily by the increased demand for refurbished syringe pumps among end-users and the development of wireless smart syringe pumps.
Read More
18 Apr 2019
Global Automated Immunoassay Analyzer Market Driven by Increase in Applications
The global automated immunoassay analyzer market is expected to achieve significant growth over the coming years, driven by innovations in the existing products and increased clinical applications of these systems.
Read More
18 Apr 2019
Global Mammography Market Driven by Increased Breast Cancer Prevalence
The growth of the global mammography market is being driven by the rising prevalence of breast cancer, technological advancements in breast imaging, and investments by various organizations in breast cancer screening campaigns.
Read More
16 Apr 2019
FDA Approves First AI-Powered Radiation Exposure Reduction Solution
An artificial intelligence (AI) powered region of interest (ROI) radiation exposure reduction solution for interventional X-ray imaging has received clearance from the US FDA.
Read More
16 Apr 2019
FDA Developing Regulatory Framework for AI-Related Medical Devices
The US Food and Drug Administration is considering a new regulatory framework specifically tailored to promote the development of safe and effective medical devices that use advanced artificial intelligence (AI) algorithms.
Read More
16 Apr 2019
Global Multi-Parameter Patient Monitoring Market to Reach USD 6 Billion by 2028
The global multi-parameter patient monitoring market is expected to grow moderately at a CAGR of 4.6% over the 2018-2028 projected period to reach USD 6 billion by the end of 2028, driven mainly by rising affluence in the emerging markets and the increasing aging population in developed economies providing a boost to healthcare spending.
Read More
Copyright © 2000-2019 TradeMed.com. All rights reserved. | Terms And Conditions